Central MA Life Sciences Report 35
there is recognition
of both this labor
market and the
abundance of life
sciences companies
vying for funding
from the same
sources to solve
similar health prob
-
lems.
"It's a very crowded space, but we are
taking a fundamentally different step,"
said Dawn Mattoon, CEO of Mercy
BioAnalytics.
Started in Cambridge and now based
in Natick, Mercy BioAnalytics research
is focused on the early detection of can
-
cer using liquid biopsies. The technology
utilizes biomarker co-localization of
blood, which carries detectable markers
of cancer. Mercy's technology is de-
signed to detect early stage cancer, when
it is most curable.
"It's an enormous unmet need," said
Mattoon.
The Natick location has allowed
Mercy to nurture itself out of the startup
phase, said Mattoon.
There's volatility in the market, but
with it comes newly available talent, too.
At MustangBio, new space brings the
need for new faces in the facility. And
bringing those new workers into the
Central Massachusetts economy has
been easy, said Manning. It's one of a
number of reasons the company has no
plans to leave the region.
"We have no trouble hiring people
here. It's just the opposite," said Man
-
ning. "We plan to stay."
MassBio.org
MassBio represents the premier life
sciences and healthcare global hub.
BECOME A
MEMBER
MassBio offers companies
countless benefits
and so much more!
Exclusive membership savings and rewards
Access to the MassBio (conference &
business center)
Workforce recruitment
115+ events annually
Hub
MassBio.org
JOIN TODAY!
Life science's economic
impact in Central Mass.
Even though they encompass more than the life sciences sector, the two
industries primarily including the sector comprise about 19% of the total GDP in
the Greater Worcester metro area.
Source: U.S. Bureau of Labor Statistics
GREATER WORCESTER METRO AREA GDP % OF TOTAL GDP
All industry total $45.2 billion
Professional, scientific, and technical services $3.5 billion 7.71%
Health care and social assistance $5.1 billion 11.34%
LS
Dawn Mattoon,
CEO of Mercy
BioAnalytics